Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Anaplastic Large Cell Lymphoma (ALCL) Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) Overview | 8 | 1 |
| Anaplastic Large Cell Lymphoma (ALCL) Therapeutics under Development by Companies | 9 | 1 |
| Anaplastic Large Cell Lymphoma (ALCL) Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Anaplastic Large Cell Lymphoma (ALCL) Products under Development by Companies | 13 | 1 |
| Anaplastic Large Cell Lymphoma (ALCL) Companies Involved in Therapeutics Development | 14 | 8 |
| Ariad Pharmaceuticals, Inc. | 14 | 1 |
| AstraZeneca Plc | 15 | 1 |
| Bayer AG | 16 | 1 |
| Celon Pharma Sp. z o.o. | 17 | 1 |
| Pfizer Inc. | 18 | 1 |
| Sareum Holdings Plc | 19 | 1 |
| Seattle Genetics, Inc. | 20 | 1 |
| Teva Pharmaceutical Industries Ltd. | 21 | 1 |
| Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Assessment | 22 | 9 |
| Assessment by Monotherapy Products | 22 | 1 |
| Assessment by Target | 23 | 2 |
| Assessment by Mechanism of Action | 25 | 2 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 2 |
| Drug Profiles | 31 | 50 |
| AdIL-24 Drug Profile | 31 | 2 |
| AZD-3463 Drug Profile | 33 | 1 |
| brentuximab vedotin Drug Profile | 34 | 21 |
| brigatinib Drug Profile | 55 | 9 |
| CEP-37440 Drug Profile | 64 | 1 |
| copanlisib hydrochloride Drug Profile | 65 | 4 |
| crizotinib Drug Profile | 69 | 7 |
| Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma Drug Profile | 76 | 1 |
| SAR-3 Drug Profile | 77 | 1 |
| SAR-4 Drug Profile | 78 | 2 |
| SH-7129 Drug Profile | 80 | 1 |
| Anaplastic Large Cell Lymphoma (ALCL) Dormant Projects | 81 | 1 |
| Anaplastic Large Cell Lymphoma (ALCL) Discontinued Products | 82 | 1 |
| Anaplastic Large Cell Lymphoma (ALCL) Product Development Milestones | 83 | 20 |
| Featured News &Press Releases | 83 | 1 |
| Jan 22, 2016: European Commission Approves Label Variation for ADCETRIS to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma | 83 | 1 |
| Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma | 84 | 1 |
| Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting | 85 | 2 |
| Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting | 87 | 2 |
| Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 | 89 | 2 |
| Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting | 91 | 1 |
| Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress | 92 | 1 |
| Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan | 93 | 1 |
| Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma | 93 | 1 |
| Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma | 94 | 2 |
| Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma | 96 | 2 |
| Jun 01, 2013: Takeda Highlights Data From Phase I/II Clinical Trial Examining Use Of Adcetris in Pediatric Patients With Hodgkin Lymphoma Or Systemic Anaplastic Large Cell Lymphoma | 98 | 1 |
| May 14, 2013: Seattle Genetics Announces Adcetris Supplemental BLA Accepted For Filing By FDA | 99 | 1 |
| Mar 22, 2013: Takeda Submits New Drug Application For Brentuximab Vedotin In Japan | 100 | 1 |
| Mar 18, 2013: Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With Adcetris In Relapsed Hodgkin Lymphoma And Systemic ALCL | 101 | 2 |
| Appendix | 103 | 2 |
| Methodology | 103 | 1 |
| Coverage | 103 | 1 |
| Secondary Research | 103 | 1 |
| Primary Research | 103 | 1 |
| Expert Panel Validation | 103 | 1 |
| Contact Us | 103 | 1 |
| Disclaimer | 104 | 1 |